Revvity is a company that operates in the advanced growth stage. With over 20 years of expertise in viral vector development and manufacturing, the company has established a strong presence in the fields of cell therapy, gene therapy, and vaccination. Revvity has successfully advanced therapies from preclinical research to market, indicating a mature and established position in the industry.

Some significant milestones in Revvity's history include the optimization of viral vectors for various applications, the development of advanced technologies such as LentiBOOST™ for improved transduction efficiency, and the evolution of AAV capsid and nanobody targeting services. The company's collaborations with pharma and biotech organizations highlight its growth and recognition in the industry, making it a key player in viral vector engineering and manufacture.

Revvity has been involved in numerous notable case studies, demonstrating the impact of its viral vector technologies on various therapies. These case studies highlight the successful delivery of gene therapy, cell therapy, and vaccination products using Revvity's viral vectors. The company's contributions to the field of viral vector engineering and manufacture have led to significant advancements in the development of novel therapies and treatments.

Key events in Revvity's history include the development and launch of new viral vector products, strategic partnerships with pharma and biotech organizations, and recognition through industry awards. The company's participation in industry conferences and forums, acquisition of advanced technologies for viral vector development, and ongoing commitment to research and development are essential events that have shaped Revvity's growth and success.